Normalization of lipoprotein lipase and hepatic lipase by gemfibrozil results in correction of lipoprotein abnormalities in chronic renal failure.
Eighteen patients with chronic renal failure (serum creatinine 173-756 mumol/l) and hyperlipidemia were treated with gemfibrozil (1200 mg/day). The drug caused a significant improvement of the dyslipidemia within one week and the effect was progressive during the 28 weeks of treatment. Very-low-density lipoprotein triglycerides and very-low-density lipoprotein cholesterol decreased by about 50% and high-density lipoprotein cholesterol increased by 30%. The lipoprotein changes occurred simultaneously with a significant activation to normal levels of postheparin plasma lipoprotein and hepatic lipases. Opposite effects were observed when gemfibrozil was discontinued and the patients were given placebo. No major harmful effects were observed.
D000328:Adult; D000368:Aged; D002986:Clinical Trials as Topic; D004789:Enzyme Activation / Q000187:drug effects; D005260:Female; D015248:Gemfibrozil; D006801:Humans; D007676:Kidney Failure, Chronic / Q000097:blood* / Q000188:drug therapy; D008049:Lipase / Q000172:deficiency*; D008071:Lipoprotein Lipase / Q000172:deficiency*; D008074:Lipoproteins / Q000097:blood; D008099:Liver / Q000201:enzymology*; D008297:Male; D008875:Middle Aged; D010421:Pentanoic Acids / Q000627:therapeutic use*; D014280:Triglycerides / Q000097:blood; D014631:Valerates / Q000627:therapeutic use*
D008074:Lipoproteins; D010421:Pentanoic Acids; D014280:Triglycerides; D014631:Valerates; D008049:Lipase; D008071:Lipoprotein Lipase; D015248:Gemfibrozil